1. Managing Complex Hypertension: What Every Physician Should Know

3. Introduction/Background

4. ESH/ESC/JNC8 Blood Pressure Treatment Recommendations

5. Complex Hypertension: Hard-to-Treat and/or With Comorbidities

6. Results From The SPRINT Trial: SBP >130? >120?

7. Controversy Surrounding BP Measurement in SPRINT

8. The J-Curve and Risk of Aggressive Blood Pressure Reduction

9. Early, Aggressive Treatment of HTN?

10. Non-Adherence to Antihypertensive Agents: Results of a Urine-Based Assay

11. Single-Pill Combinations vs Free Drug Components: Effects on Compliance

12. The Treatment-Resistant Hypertensive Patient

13. (Apparent) Resistant HTN Patients With Appropriate Triple Therapy

14. Non-Adherence and the Older Hypertensive Patient

15. Improving Adherence to Therapy: Patient Communication Strategies

16. Medical Complications of Hypertension

17. End-Organ Damage Associated With Chronic Hypertension

18. The Cardiovascular-Renal Continuum in The Context of Hypertension

19. Prevalence of HTN in Selected AF Trials

20. Antihypertensive Single-Pill Combination Therapy Compared to Monotherapy and Placebo: A Subgroup Analysis

21. Current Dosages of Hydrochlorothiazide for HTN May Be Suboptimal

22. Superior BP Reduction With Initial Combination Therapy

23. Initial Combination HTN Therapy Reduces CV Event Rates

24. LEADER: Primary Outcome Liraglutide vs Placebo*

25. EMPA-REG: Primary Outcome (3-Point MACE) CV Death, Nonfatal MI, or Nonfatal Stroke

26. Summary and Conclusions

27. Abbreviations

28. Abbreviations (cont)